Matthew Koshy1, Renuka Malik, Mike Spiotto, Usama Mahmood, Ralph Weichselbaum, David Sher. 1. *Department of Radiation Oncology, University of Illinois at Chicago, Chicago, Illinois; †Department of Radiation and Cellular Oncology, The University of Chicago, Chicago, Illinois; ‡Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas; and §Department of Radiation Oncology, Rush University Medical Center, Chicago, Illinois.
Abstract
BACKGROUND: Patients unable to receive surgery for stage I non-small cell lung cancer (NSCLC) can undergo conventional radiotherapy (ConvRT), stereotactic body radiotherapy (SBRT), or no treatment (NoTx). This study assessed patterns of care and disparities in the receipt of each of these treatments. METHODS: The study included patients in the National Cancer Database from 2003 to 2011 with T1-T2N0M0 inoperable lung cancer (n = 39,822). Logistic regressions were performed to determine predictors of receiving any radiation versus NoTx and for receiving SBRT versus ConvRT. RESULTS: Treatment with radiation was significantly less likely in blacks (odds ratio, OR 0.65) and Hispanics (OR 0.42) compared with whites. Treatment with SBRT versus ConvRT was more likely in an academic research program (OR 2.62) and a high-volume facility (OR 7.00) compared with community cancer programs or low-volume facilities. In 2011, use of SBRT, ConvRT, and NoTx was 25%, 28%, and 46% for patients in a community cancer center versus 68%, 11%, and 21%, respectively, in an academic center (p < 0.0001). CONCLUSION: There were marked institutional and socioeconomic variations in the treatment of inoperable stage I NSCLC. These results suggest that removal of barriers to receive radiation therapy and particularly improved access to SBRT may meaningfully improve survival in this disease.
BACKGROUND:Patients unable to receive surgery for stage I non-small cell lung cancer (NSCLC) can undergo conventional radiotherapy (ConvRT), stereotactic body radiotherapy (SBRT), or no treatment (NoTx). This study assessed patterns of care and disparities in the receipt of each of these treatments. METHODS: The study included patients in the National Cancer Database from 2003 to 2011 with T1-T2N0M0 inoperable lung cancer (n = 39,822). Logistic regressions were performed to determine predictors of receiving any radiation versus NoTx and for receiving SBRT versus ConvRT. RESULTS: Treatment with radiation was significantly less likely in blacks (odds ratio, OR 0.65) and Hispanics (OR 0.42) compared with whites. Treatment with SBRT versus ConvRT was more likely in an academic research program (OR 2.62) and a high-volume facility (OR 7.00) compared with community cancer programs or low-volume facilities. In 2011, use of SBRT, ConvRT, and NoTx was 25%, 28%, and 46% for patients in a community cancer center versus 68%, 11%, and 21%, respectively, in an academic center (p < 0.0001). CONCLUSION: There were marked institutional and socioeconomic variations in the treatment of inoperable stage I NSCLC. These results suggest that removal of barriers to receive radiation therapy and particularly improved access to SBRT may meaningfully improve survival in this disease.
Authors: Matthew Koshy; Stacey A Fedewa; Renu Malik; Mark K Ferguson; Wickii T Vigneswaran; Lawrence Feldman; Andrew Howard; Khaled Abdelhady; Ralph R Weichselbaum; Katherine S Virgo Journal: J Thorac Oncol Date: 2013-07 Impact factor: 15.609
Authors: Jeffrey A Bogart; Lydia Hodgson; Stephen L Seagren; A William Blackstock; Xiaofei Wang; Robert Lenox; Andrew T Turrisi; John Reilly; Ajeet Gajra; Everett E Vokes; Mark R Green Journal: J Clin Oncol Date: 2009-11-23 Impact factor: 44.544
Authors: Juan P Wisnivesky; Ethan Halm; Marcelo Bonomi; Charles Powell; Emilia Bagiella Journal: Am J Respir Crit Care Med Date: 2009-11-05 Impact factor: 21.405
Authors: Dan J Raz; Jason A Zell; S-H Ignatius Ou; David R Gandara; Hoda Anton-Culver; David M Jablons Journal: Chest Date: 2007-05-15 Impact factor: 9.410
Authors: Norma E Farrow; Selena J An; Paul J Speicher; David H Harpole; Thomas A D'Amico; Jacob A Klapper; Matthew G Hartwig; Betty C Tong Journal: J Thorac Cardiovasc Surg Date: 2019-11-13 Impact factor: 5.209
Authors: Julie K Jang; Scott M Atay; Li Ding; Elizabeth A David; Sean C Wightman; Anthony W Kim; Jason C Ye Journal: Am J Clin Oncol Date: 2022-04-01 Impact factor: 2.339
Authors: Sarah Baker; Katerina Bakunina; Marloes Duijm; Mischa S Hoogeman; Robin Cornelissen; Imogeen Antonisse; John Praag; Wilma D Heemsbergen; Joost Jan Nuyttens Journal: Radiat Oncol Date: 2020-04-22 Impact factor: 3.481
Authors: William W Chance; Karen J Ortiz-Ortiz; Kai-Ping Liao; Diego E Zavala Zegarra; Michael C Stauder; Sharon H Giordano; Guillermo Tortolero-Luna; B Ashleigh Guadagnolo Journal: J Glob Oncol Date: 2017-05-11